22 November 2021

Lecanemab for treating early Alzheimer’s disease

Lecanemab is currently in clinical development for the treatment of early Alzheimer’s disease (AD). AD is a progressive neurological disease which is caused by loss of function and death of neurones in the brain. It is the most common type of dementia.